| Document Date: 2012-06-27 15:02:02
Open Document File Size: 609,58 KBShare Result on Facebook
City St. Laurent / Cambridge / / Company AEs / Momenta Pharmaceuticals Inc / Amax / / Country United States / Canada / / Facility American College of Cardiology/American Heart Association Task Force / / MedicalCondition AE Preferred Term* General Disorders / myocardial infarction / Acute Coronary Syndromes / Patients With ST-Elevation Myocardial Infarction / heparin-induced thrombocytopenia / Injection site erythema / Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction / unstable angina/non ST-elevation / / MedicalTreatment pharmacotherapy / adjunctive therapy / / Organization the American College / Subcutaneous Administration of M118 / Cardiology/American Heart Association Task Force on Practice Guidelines / / Person Linear Scales / Semi-Log Scales / / Position King / General / / Product Single-dose SC injection / Subcutaneous Injection / Injection site bruising Injection site discolouration Injection / protamine sulfate / Administration Site Conditions Injection / / ProvinceOrState Quebec / / Technology Pharmacokinetics / Pharmacodynamics / /
SocialTag |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of M118, a Novel Rationally Engineered Low Molecular Weight Heparin Given as a Subcutaneous Injection in a Rising Dose Cohort Regimen in Healthy Subjects S. Bou